Novelos Claims Securities Action Strikes Out

Law360, New York (September 12, 2011, 3:26 PM EDT) -- Novelos Therapeutics Inc. argued Friday that a putative class of investors alleging the company misled them about the prospects of a developmental-stage cancer drug had failed for a third time to state a claim, and thus the complaint should be dismissed for good.

In a motion to dismiss filed in Boston federal court, Novelos said that new claims in a second amended complaint filed in August alleging that the company changed the formula of lung cancer drug NOV-002 in 2005 without approval from the U.S. Food...
To view the full article, register now.




Case Information

Case Title

Urman, et al v. Novelos Therapeutics, Inc. et al

Case Number




Nature of Suit



Nathaniel M. Gorton

Date Filed

March 5, 2010

Law Firms

Government Agencies

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.